SCHEMBL21777955

SCHEMBL21777955

C=Cc1cc(C(=O)O)c(=O)n(-c2ccc(F)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.53
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
NOTUM Q6P988 1/20 0.40
RECQL P46063 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALDH1A1 P00352 3/20 0.37
HPGD P15428 2/20 0.37
HSD17B10 Q99714 1/20 0.37
ESR1 P03372 3/20 0.37
ESR2 Q92731 3/20 0.37
MAPK1 P28482 1/20 0.36
TP53 P04637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KCNH2 Q12809 1/20 0.35
HTT P42858 1/20 0.34
ESRRA P11474 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30838382 0.85 MEN1 (0.47) LMNAKDM4EKMT2AMEN1L3MBTL1
SCHEMBL21777459 0.84 MEN1 (0.57) LMNAKDM4EKMT2AMEN1RECQL
SCHEMBL21785488 0.84 LMNA (0.51) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL21797956 0.84 LMNA (0.51) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL21383288 0.78 MAPK1 (0.58) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL4070919 0.78 KDM4E (0.57) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL679241 0.78 LMNA (0.57) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL21777741 0.77 LMNA (0.52) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL23147088 0.76 LMNA (0.55) LMNAKDM4EKMT2AMEN1NOTUM
SCHEMBL4074927 0.75 LMNA (0.53) LMNAKDM4EKMT2AMEN1NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119546587-A Substituted pyridone compounds as CBL-B inhibitors 格兰玛克制药有限公司 2025-02-28 CN disclosed
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2024-05-30 US disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 EP disclosed
EP-3843850-B1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC (US) 2023-11-15 EP disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases ARRAY BIOPHARMA INC. (US) 2023-10-10 US disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 US disclosed
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2023-01-12 US disclosed
EP-3843850-A1 PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES Array BioPharma Inc. (US) 2021-07-07 EP disclosed
CN-112930215-A Pyrazolo [3, 4-b ] pyridine compounds as TAM and MET kinase inhibitors 阿雷生物药品公司 2021-06-08 CN disclosed
US-20200079770-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. 2020-03-12 US disclosed
WO-2020047184-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2020-03-05 WO disclosed
WO-2020047184-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES ARRAY BIOPHARMA INC. (US) 2020-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230011441-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET LMNA 3554/4885KDM4E 935/4885KMT2A 1307/4885
US-20240174666-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET LMNA 3447/4885KDM4E 951/4885KMT2A 1340/4885
US-20200079770-A1 PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES RET, MERTK, MET LMNA 3447/4885KDM4E 951/4885KMT2A 1340/4885
US-11780835-B2 Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases RET, MERTK, MET LMNA 3554/4885KDM4E 935/4885KMT2A 1307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.